XML 49 R38.htm IDEA: XBRL DOCUMENT
v3.24.3

License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, £ in Millions |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 15, 2021 USD ($) | Jun. 30, 2017 USD ($) | Jun. 30, 2016 USD ($) | Jun. 30, 2016 GBP (£) | May 31, 2016 USD ($) | Sep. 30, 2024 USD ($) $ / shares | Mar. 31, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2020 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Jun. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) $ / shares shares | Sep. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) | Sep. 30, 2025 USD ($) | Mar. 31, 2025 USD ($) | Oct. 31, 2024 USD ($) | Aug. 31, 2024 USD ($) | Jun. 30, 2024 USD ($) | Jul. 31, 2023 USD ($) | Nov. 07, 2022 USD ($) | Oct. 31, 2017 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of stock, value |  |  |  |  |  |  |  | $ 220,000 |  |  |  |  |  |  | $ 220,000 |  |  |  |  |  |  |  |  |  |
Common stock, par value | $ / shares |  |  |  |  |  | $ 0.001 |  |  |  |  |  |  |  | $ 0.001 |  | $ 0.001 |  |  |  |  |  |  |  |  |
Proceeds from sale of common stock to related party |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | 220,000 |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 65,000 |  | 218,000 |  |  |  |  |  | 319,000 | 710,000 |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 225,000,000 |  |  |  |  |  |  |  | 225,000,000 |  |  |  |  |  |  |  |  |  |  |
Total Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 95,000,000 |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  | 788,000 |  |  |  |  |  |  |  | 788,000 |  | 2,132,000 |  |  |  |  |  |  |  |  |
GSK SPA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining transaction price allocated to the performance obligations |  |  |  |  |  | 64,700,000 |  |  |  |  |  |  |  | 64,700,000 |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 21,200,000 |  |  |  |  |  |  |  | 21,200,000 |  |  |  |  |  |  |  |  |  |  |
Total Milestone |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  |  |  |  |  |
Initial Payments to Perform the Obligations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 66,000,000 |  |  |  |  |  |  |  |
Discount on Obligations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,300,000 |  |  |  |  |  |  |  |
GSK SPA [Member] | Research And Development Services Related To Upcoming Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,000,000 |  |  |  |  |  |  |  |
GSK SPA [Member] | License and Know-How Transfer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining transaction price allocated to the performance obligations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 64,700,000 |  |  |  |  |  |  |  |
Performance Obligation Allocated Transaction Price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,700,000 |  |  |  |  |  |  |  |
Vertex License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement research and development expense related to achievement of regulatory milestones |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  | $ 0 | 0 |  |  |  |  |  |  |  |  |  |
Contract termination period |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payments |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones |  |  |  |  | $ 80,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract termination period if no material development or commercialization occurs |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |
GSK License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance Obligation Allocated Transaction Price |  |  |  |  |  | 7,800,000 |  | 23,200,000 |  |  |  |  |  | $ 17,700,000 | 24,200,000 |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  | 30,900,000 |  |  |  |  |  |  |  | 30,900,000 |  |  |  |  |  |  |  |  |  |  |
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total potential additional milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,200,000 |  |  |  |  |  |  |  |  |
GSK License Agreement [Member] | Amendment 2 [Member] | First Milestone [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200,000 |  |  |  |
GSK License Agreement [Member] | Glaxo Smith Kline [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,800,000 |  | $ 23,800,000 | $ 23,800,000 |  |  | $ 23,800,000 |  | $ 66,000,000 |
Reduction In Subsequent Payments by GSK to the Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 2 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,300,000 |  |
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 2 [Member] | Second Milestone [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  |  |
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 4 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000 |  |  |  |  |
GSK License Agreement [Member] | GSK SPA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 23,800,000 | $ 23,800,000 |  |  |  |  |  |  | 23,800,000 |  | 64,700,000 |  | $ 23,800,000 | $ 23,800,000 |  |  |  | $ 30,000,000 |  |
Total Received Milestone |  |  |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  | 30,000,000 | 95,000,000 |  |  |  |  |  |  |  |  |
Significant financing component |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |  |  |  |  |  |  |
Total Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 95,000,000 |  |  |  |  |  |  |  |  |
Research and development services performance obligation |  |  |  |  |  | 8,800,000 |  |  |  |  |  |  |  | 8,800,000 |  | 2,500,000 |  |  |  |  |  |  |  |  |
Meiji License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payments |  | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sublicense fee payable to counter party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,500,000 |  |  |  |  |  |  |  |
Potential milestone payments upon achievement of specified condition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000
License agreement fixed assets related payments |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments upon completion and delivery of results of a clinical study |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |  |  |  |  |  |  |
Sublicence Fee Paid to Counter Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,600,000 |  |  |  |  |  |  |  |
Remaining Sublicence Fee Paid to Counter Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 900,000 |  |  |  |  |  |  |  |  |
Cantab Related Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified commercial milestone |  |  |  | £ 5.0 |  |  |  |  |  |  |  |  |  | 6,700,000 |  |  |  |  |  |  |  |  |  |  |
License agreement research and development expense related to achievement of regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones |  |  | $ 5,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of option granted on an agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 months |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments upon completion and delivery of results of a clinical study |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 0 |  | 0 |  |  |  |  |  | $ 0 | 0 |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 34,000,000 |  |  |  |  |  |  |  | 34,000,000 |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] | SPR 206 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payment received | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] | SPR 741 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period upon written notice | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] | Maximum [Member] | SPR 206 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable amount upon achievement of certain milestone | $ 38,000,000 |  |  |  |  | 59,500,000 |  |  |  |  |  |  |  | $ 59,500,000 |  |  |  |  |  |  |  |  |  |  |
Everest License Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period upon written notice | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pfizer License and Share Purchase Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable amount upon achievement of certain milestone |  |  |  |  |  |  |  |  | $ 900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payment received |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of stock, shares | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,362,348 |  |  |  |  |  |  |  |  |  |  |
Issuance of stock, value |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 27,500,000 |  |  |  |  |  |  |  |  |  |  |
Remaining transaction price allocated to the performance obligations |  |  |  |  |  | 12,500,000 |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 100,000 |  | $ 200,000 |  |  |  |  |  | 300,000 | $ 700,000 |  |  |  |  |  |  |  |  |  |
Premium associated freestanding equity |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |  |  |  |  |  |  |
Performance Obligation Allocated Transaction Price |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  | $ 12,600,000 |  |  |  |  |  |  |  | 12,600,000 |  |  |  |  |  |  |  |  |  |  |
Pfizer License and Share Purchase Agreements [Member] | SPR 206 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable amount upon achievement of certain milestone |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000 |  |  |  |  |  |  |  |  |  |  |
Issuance of stock, shares | shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,362,348 |  |  |  |  |  |  |  |  |  |  |
Share price | $ / shares |  |  |  |  |  | $ 16.93 |  |  |  |  |  |  |  | $ 16.93 |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of common stock to related party |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance Obligation Allocated Transaction Price |  |  |  |  |  |  |  |  | $ 4,100,000 |  |  |  |  | 11,100,000 |  |  |  |  |  |  |  |  |  |  |
Pfizer License and Share Purchase Agreements [Member] | License and Know-How Transfer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Performance Obligation Allocated Transaction Price |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payments receivable upon achievement of certain developmental regulatory and sales milestone. + References No definition available. + Details
Name: | spro_AdditionalMilestonePaymentsReceivableUponAchievementOfCertainDevelopmentalRegulatoryAndSalesMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement termination period upon written notice. + References No definition available. + Details
Name: | spro_AgreementTerminationPeriodUponWrittenNotice
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Change in subsequent payments + References No definition available. + Details
Name: | spro_ChangeInSubsequentPayments
Namespace Prefix: | spro_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Contract termination period. + References No definition available. + Details
Name: | spro_ContractTerminationPeriod
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contract termination period if no material development or commercialization occurs. + References No definition available. + Details
Name: | spro_ContractTerminationPeriodIfNoMaterialDevelopmentOrCommercializationOccurs
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Discount on Obligations. + References No definition available. + Details
Name: | spro_DiscountOnObligations
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Initial Payments to Perform the Obligations. + References No definition available. + Details
Name: | spro_InitialPaymentsToPerformTheObligations
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement fixed assets related payments. + References No definition available. + Details
Name: | spro_LicenseAgreementFixedAssetsRelatedPayments
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement future milestone payments. + References No definition available. + Details
Name: | spro_LicenseAgreementFutureMilestonePayments
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payment upon completion and delivery of results of a clinical study. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentUponCompletionAndDeliveryOfResultsOfClinicalStudy
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified clinical, regulatory and commercial milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedClinicalRegulatoryAndCommercialMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified commercial milestone. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementOfSpecifiedCommercialMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon achievement of specified pivotal condition. + References No definition available. + Details
Name: | spro_LicenseAgreementMilestonePaymentsUponAchievementSpecifiedPivotalCondition
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License agreement research and development expense related to achievement of regulatory milestones. + References No definition available. + Details
Name: | spro_LicenseAgreementResearchAndDevelopmentExpenseRelatedToAchievementOfRegulatoryMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone Allocated Research And Development Services + References No definition available. + Details
Name: | spro_MilestoneAllocatedResearchAndDevelopmentServices
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestone payment upon submission of a new drug application. + References No definition available. + Details
Name: | spro_MilestonePaymentUponSubmissionOfANewDrugApplication
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Milestones payment received + References No definition available. + Details
Name: | spro_MilestonesPaymentReceived
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable up front payment received. + References No definition available. + Details
Name: | spro_NonRefundableUpFrontPaymentReceived
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Performance Obligation Allocated Transaction Price + References No definition available. + Details
Name: | spro_PerformanceObligationAllocatedTransactionPrice
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period of option granted on an agreement. + References No definition available. + Details
Name: | spro_PeriodOfOptionGrantedOnAgreement
Namespace Prefix: | spro_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Receivable amount upon achievement of certain milestone. + References No definition available. + Details
Name: | spro_ReceivableAmountUponAchievementOfCertainMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Remaining Sublicence Fee Paid to Counter Party + References No definition available. + Details
Name: | spro_RemainingSublicenceFeePaidToCounterParty
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Remaining Transaction price allocated to performance obligations. + References No definition available. + Details
Name: | spro_RemainingTransactionPriceAllocatedToPerformanceObligations
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Significant financing component + References No definition available. + Details
Name: | spro_SignificantFinancingComponent
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sublicence Fee Paid to Counter Party + References No definition available. + Details
Name: | spro_SublicenceFeePaidToCounterParty
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sublicense fee payable to counterparty. + References No definition available. + Details
Name: | spro_SublicenseFeePayableToCounterparty
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total milestone + References No definition available. + Details
Name: | spro_TotalMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total potential additional milestones + References No definition available. + Details
Name: | spro_TotalPotentialAdditionalMilestones
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total Received Milestone + References No definition available. + Details
Name: | spro_TotalReceivedMilestone
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | spro_UpfrontPaymentReceived
Namespace Prefix: | spro_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow to separate account liability from premium collected from policyholder. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480109/944-80-50-2 + Details
Name: | us-gaap_SeparateAccountLiabilityPremium
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spro_GskSpaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_ResearchAndDevelopmentServicesRelatedToUpcomingMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_LicenseAndKnowHowTransferMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_VertexLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_GskLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=spro_AmendmentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_FirstMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spro_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_SecondMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=spro_AmendmentFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_MeijiLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_CantabRelatedAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_EverestLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_SPRTwoZeroSixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=spro_SPRSevenFourOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spro_PfizerLicenseAndSharePurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |